Search

Displaying results 1271 - 1280 of 10000 in total
  1. Target

    Low affinity immunoglobulin gamma Fc region receptor II-a

    go.drugbank.com/bio_entities/BE0002098
    TargetHumans

    Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens

    Polypeptides: Low affinity immunoglobulin gamma Fc region receptor II-aSynonyms: IgG Fc receptor II-a
  2. Target

    Transient receptor potential cation channel subfamily V member 2

    go.drugbank.com/bio_entities/BE0009158
    TargetHumans

    Calcium-permeable, non-selective cation channel (PubMed:10201375). Seems to be regulated, at least in part, by growth factors, such as IGF1, PDGF and morphogenetic neuropeptide/head activator. May transduce physical stimuli in mast cells...

    Polypeptides: Transient receptor potential cation channel subfamily V member 2Synonyms: Vanilloid receptor-like protein 1
  3. Target

    Ankyrin repeat and protein kinase domain-containing protein 1

    go.drugbank.com/bio_entities/BE0009411
    TargetHumans

    Polypeptides: Ankyrin repeat and protein kinase domain-containing protein 1
  4. Target

    Transient receptor potential cation channel subfamily M member 3

    go.drugbank.com/bio_entities/BE0009808
    TransporterHumans

    Suggested to function as an ionotropic steroid receptor in beta-cell, indeed pregnenolone sulfate leads to Ca(2+) influx and enhanced insulin secretion.

    Polypeptides: Transient receptor potential cation channel subfamily M member 3Synonyms: Long transient receptor potential channel 3
  5. Drug

    Bexicaserin

    go.drugbank.com/drugs/DB18885
    Investigational

    Bexicaserin is under investigation in clinical trial NCT05626634 (Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy).

  6. Drug

    Fosigotifator

    go.drugbank.com/drugs/DB19409
    Investigational

    Fosigotifator is under investigation in clinical trial NCT05757141 (An Open-label Exploratory Study of ABBV-CLS-7262 Subjects With Vanishing White Matter Disease).

  7. Drug

    Thiocolchicoside

    go.drugbank.com/drugs/DB11582
    Investigational

    It has potent convulsant activity and should not be administered to individuals prone to seizures.[L1663] … Thiocolchicoside is a semi-synthetic derivative of the colchicine, a natural anti-inflammatory glycoside which originates from the flower seeds of _Superba gloriosa_.

    Products: MUSCORIL CONTRATTURE E DOLORE, MIOTENS CONTRATTURE E DOLORE
  8. Drug

    ANZ-100

    go.drugbank.com/drugs/DB05967
    Investigational

  9. Drug

    Caffeine

    go.drugbank.com/drugs/DB00201
    ApprovedInvestigational

    [T716] The caffeine citrate injection, used for apnea of the premature newborn, was initially approved by the FDA in 1999. … Caffeine is a drug of the methylxanthine class used for a variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and to combat drowsiness.

    Mixtures: ANDOX T, Headache Relief to GoProducts: CITRATO DE CAFEINA 20 MG/ML . SOLUCION ESTERIL, PEYONA 20MG/ML INFÜZYONLUK VE ORAL ÇÖZELTI, 10 AMPUL
  10. Drug

    Azintuxizumab vedotin

    go.drugbank.com/drugs/DB14847
    Investigational

    Recent Cancer Treatment). … investigation in clinical trial NCT02951117 (A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to